Trial Profile

An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy as First-Line Treatment in Participants With PD-L1 High (≥50% of Tumor Cells Expressing PD-L1), Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (BE6A LUNG-02)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 May 2025 Status changed from not yet recruiting to recruiting.
07 Mar 2025 Planned End Date changed from 17 Feb 2029 to 1 Mar 2029.
07 Mar 2025 Planned primary completion date changed from 24 Aug 2028 to 5 Sep 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com